TFF Pharmaceuticals (TFFP)
(Real Time Quote from BATS)
$1.74 USD
0.00 (0.00%)
Updated Jul 24, 2024 01:24 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Price, Consensus and EPS Surprise
TFFP 1.74 0.00(0.00%)
Will TFFP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TFFP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TFFP
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
TFFP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Other News for TFFP
One new option listing and eighteen option delistings on July 22nd
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
TFF Pharmaceuticals engages Outcome Capital as strategic advisor
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals submits briefing book to the FDA for TFF TAC development